Applied Therapeutics, Inc. financial data

Symbol
APLT on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 212 % +50.3%
Debt-to-equity 94.8 % -61%
Return On Equity -65.6 % +88.8%
Return On Assets -33.7 % +80.2%
Operating Margin -9.85K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 144M shares +24%
Common Stock, Shares, Outstanding 144M shares +24%
Entity Public Float 478M USD +648%
Common Stock, Value, Issued 35K USD +218%
Weighted Average Number of Shares Outstanding, Basic 146M shares +0.84%
Weighted Average Number of Shares Outstanding, Diluted 146M shares +0.84%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 999K USD +720%
Research and Development Expense 39.1M USD -25.4%
General and Administrative Expense 60.3M USD +51.9%
Operating Income (Loss) -98.4M USD -6.63%
Nonoperating Income (Expense) 80.3M USD +94.3%
Net Income (Loss) Attributable to Parent -18.1M USD +90.3%
Earnings Per Share, Basic 0 USD/shares +96.1%
Earnings Per Share, Diluted 0 USD/shares +72.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.9M USD -87.9%
Cash, Cash Equivalents, and Short-term Investments 22.9M USD -58.9%
Other Assets, Current 255K USD -30.3%
Assets, Current 31.7M USD -69.7%
Operating Lease, Right-of-Use Asset 2.47M USD +25.7%
Assets 34.4M USD -67.7%
Accounts Payable, Current 4.8M USD +69.2%
Contract with Customer, Liability, Current 212K USD 0%
Liabilities, Current 32.9M USD -66.8%
Operating Lease, Liability, Noncurrent 2.03M USD +19.1%
Liabilities 34.9M USD -65.3%
Retained Earnings (Accumulated Deficit) -636M USD -2.93%
Stockholders' Equity Attributable to Parent -561K USD -110%
Liabilities and Equity 34.4M USD -67.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.6M USD -51.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 144M shares +24%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -28.6M USD -130%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 11.9M USD -87.9%
Deferred Tax Assets, Valuation Allowance 181M USD +19.5%
Deferred Tax Assets, Gross 182M USD +20%
Operating Lease, Liability 2.5M USD +26.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -106M USD +11.8%
Lessee, Operating Lease, Liability, to be Paid 3.33M USD +17.6%
Operating Lease, Liability, Current 467K USD +76.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 803K USD +44.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 803K USD +47.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 828K USD -3.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 823K USD +49.6%
Deferred Tax Assets, Operating Loss Carryforwards 115M USD +22.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 702K USD +24.7%
Additional Paid in Capital 636M USD +1.87%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 870K USD +526%
Share-based Payment Arrangement, Expense 13.9M USD +74.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%